320 related articles for article (PubMed ID: 29141650)
1. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
3. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
Parish WJ; Mark TL; Zarkin GA; Weber E
Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
[TBL] [Abstract][Full Text] [Related]
4. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
Peter SC; Murphy JG; Witkiewitz K; Hand SB; Thomas F; Johnson KC; Cowan R; Harris M; Derefinko KJ
Trials; 2023 Mar; 24(1):237. PubMed ID: 36991453
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
6. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
7. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
[TBL] [Abstract][Full Text] [Related]
8. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
9. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
Balhara YPS; Singh S; Sarkar S
Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
[TBL] [Abstract][Full Text] [Related]
10. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
[TBL] [Abstract][Full Text] [Related]
11. Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.
Bastien G; Abboud A; McAnulty C; Elkrief L; Ledjiar O; Socias ME; Le Foll B; Bahji A; Brissette S; Marsan S; Jutras-Aswad D
J Dual Diagn; 2024; 20(3):189-200. PubMed ID: 38580298
[TBL] [Abstract][Full Text] [Related]
12. A pilot investigation of the effect of electronic cigarettes on smoking behavior among opioid-dependent smokers.
Felicione NJ; Enlow P; Elswick D; Long D; Sullivan CR; Blank MD
Addict Behav; 2019 Apr; 91():45-50. PubMed ID: 30006020
[TBL] [Abstract][Full Text] [Related]
13. Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use.
Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Yalçın-Şahiner Ş; Ağtaş-Ertan E; Özgür-İlhan İ
Eur J Pharmacol; 2022 Apr; 921():174862. PubMed ID: 35271823
[TBL] [Abstract][Full Text] [Related]
14. Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population.
Hasan MM; Noor-E-Alam M; Shi J; Young LD; Young GJ
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):481-491. PubMed ID: 35670828
[No Abstract] [Full Text] [Related]
15. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
[TBL] [Abstract][Full Text] [Related]
16. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
Montalvo C; Genovese N; Renner J
Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
[No Abstract] [Full Text] [Related]
17. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava A; Kahan M; Nader M
Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
[TBL] [Abstract][Full Text] [Related]
18. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
Sullivan JG; Webster L
Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
[TBL] [Abstract][Full Text] [Related]
19. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India.
Ghosh A; Shaktan A; Basu D; Bn S; Naik SS; Mattoo SK
J Psychoactive Drugs; 2024; 56(3):364-372. PubMed ID: 37318513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
